Enhanced targeting with heterobivalent ligands.
A novel approach to specifically target tumor cells for detection and treatment is the proposed use of heteromultivalent ligands, which are designed to interact with, and noncovalently crosslink, multiple different cell surface receptors. Although enhanced binding has been shown for synthetic homomultivalent ligands, proof of cross-linking requires the use of ligands with two or more different binding moieties. As proof-of-concept, we have examined the binding of synthetic heterobivalent ligands to cell lines that were engineered to coexpress two different G-protein-coupled human receptors, i.e., the human melanocortin 4 receptor (MC4R) expressed in combination with either the human delta-opioid receptor (deltaOR) or the human cholecystokinin-2 receptor (CCK2R). Expression levels of these receptors were characterized by time-resolved fluorescence saturation binding assays using Europium-labeled ligands; Eu-DPLCE, Eu-NDP-alpha-MSH, and Eu-CCK8 for the deltaOR, MC4R, and CCK2R, respectively. Heterobivalent ligands were synthesized to contain a MC4R agonist connected via chemical linkers to either a deltaOR or a CCK2R agonist. In both cell systems, the heterobivalent constructs bound with much higher affinity to cells expressing both receptors, compared with cells with single receptors or to cells where one of the receptors was competitively blocked. These results indicate that synthetic heterobivalent ligands can noncovalently crosslink two unrelated cell surface receptors, making feasible the targeting of receptor combinations. The in vitro cell models described herein will lead to the development of multivalent ligands for target combinations identified in human cancers.
Xu
Liping
L
Department of Pharmaceutical Analytics, Pharmaceutical Institute, University of Tuebingen, Tuebingen, Germany.
Vagner
Josef
J
Josan
Jatinder
J
Lynch
Ronald M
RM
Morse
David L
DL
Baggett
Brenda
B
Han
Haiyong
H
Mash
Eugene A
EA
Hruby
Victor J
VJ
Gillies
Robert J
RJ
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D001667:Binding, Competitive; D016466:CHO Cells; D002478:Cells, Cultured; D006224:Cricetinae; D003412:Cricetulus; D006801:Humans; D008024:Ligands; D009942:Organometallic Compounds / Q000737:chemistry / Q000494:pharmacology*; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology*; D043887:Receptor, Cholecystokinin B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D044105:Receptor, Melanocortin, Type 4 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D017465:Receptors, Opioid, delta / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014162:Transfection; D000521:alpha-MSH / Q000031:analogs & derivatives / Q000494:pharmacology
D000970:Antineoplastic Agents; D008024:Ligands; C470072:MC4R protein, human; D009942:Organometallic Compounds; D010455:Peptides; D043887:Receptor, Cholecystokinin B; D044105:Receptor, Melanocortin, Type 4; D017465:Receptors, Opioid, delta; D000521:alpha-MSH; D004369:Pentetic Acid